Risk of rash and stomatitis with everolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.

e15031 Background: Temsirolimus, an mTOR inhibitor, is approved for treatment of advanced renal cell carcinoma (RCC). Maculopapular/acneiform rash and stomatitis are the most common mucocutaneous toxicities. We systematically investigated the overall incidence and risk of rash and stomatitis in patients receiving temsirolimus. Methods: Relevant studies were identified from PubMed database (1999-2010) and abstracts presented at the American Society of Clinical Oncology Conferences between 2004 and 2010. A citation database Web of Science was searched to ensure that no relevant studies were missed. Eligible studies were limited to prospective Phase II-III clinical trials and expanded-access programs in which cancer patients received temsirolimus 25 mg weekly as a single agent. Incidence, relative risk (RR), and 95% confidence intervals were calculated using random-effects or fixed-effects models based on heterogeneity of included studies. Results: A total of 579 patients from 10 clinical trials were availab...